Latest news and press releases about Johnson & Johnson (JNJ): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Price
| Price | $252.93 |
| Market Cap | $609.5B |
| Exchange | NYSE |
| Country | US |
Valuation Ratios
| P/E Ratio | 29.67 |
| Price / Book | 6.18 |
| EV / EBITDA | 12.97 |
| Dividend Yield | 2.46% |
Profitability
| Return on Equity | 32.87% |
| Return on Invested Capital | 13.71% |
| Return on Assets | 13.46% |
| Gross Margin | 67.88% |
| Operating Margin | 27.17% |
| Net Margin | 28.46% |
Related companies: ABBV · AMGN · AZN · GILD · MRK · NVO · NVS
Explore sector: Healthcare · Drug Manufacturers - General
More sections of JNJ: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks